Breast health

Mammogram Benefits and Harms: An Honest Ledger

Save

Mammograms both help and harm, so an honest choice weighs both. Regular screening lowers breast cancer deaths, the clear benefit. The main harms are false positives, about half of women screened yearly for 10 years get one, and overdiagnosis, finding cancers that would never have caused symptoms. For average-risk women, most experts judge the benefit worth it.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What is the benefit of mammogram screening?

The central benefit of mammography is fewer deaths from breast cancer. By finding tumors before they can be felt, screening allows earlier, often less aggressive treatment, and the National Cancer Institute concludes that regular mammograms reduce breast cancer mortality 1. The size of that benefit rises with age, because breast cancer becomes more common as women get older; about 1 in 8 women develops it over a lifetime, most after age 50 1. For women in their 40s the absolute benefit is smaller, since the disease is less common, while for women in their 60s and early 70s it is larger 1. Guidelines agree the mortality benefit is real; they differ on how large it is at each age.

How common are false positives?

False positives are the most frequent harm of screening. A false positive means a mammogram flags something that, after more imaging or a biopsy, turns out not to be cancer. According to the National Cancer Institute, about half of women screened annually for 10 years will have at least one false positive, and a smaller share will undergo a biopsy that proves benign 1. These callbacks cause anxiety, cost, and occasional procedures, though they rarely cause physical harm. Rates are highest in younger women and those with dense breasts, because dense tissue is harder to read 1. Choosing screening every two years rather than every year roughly halves the cumulative false-positive rate while keeping most of the benefit 1.

What is overdiagnosis and why does it matter?

Overdiagnosis is the subtler harm: finding a cancer that never would have caused symptoms or shortened life. Because some tumors grow very slowly or not at all, screening can detect disease that would have stayed silent, yet once found it is usually treated with surgery, radiation, or medication 1. The National Cancer Institute stresses that overdiagnosis cannot be identified in any single woman and that estimates vary widely, from a small fraction to a substantial share of screen-detected cancers 1. This uncertainty is exactly why guidelines weigh the harm differently. Overdiagnosis matters most later in life, when other conditions compete, which is one reason the decision to stop screening hinges on overall health.

How do risk level and age change the balance?

Where the benefit-harm balance settles depends heavily on your personal risk. For a woman at higher risk, such as those with a BRCA gene change or strong family history, the benefit of finding cancer early is larger, so earlier and more intensive screening is advised 3. Personal factors also shift risk: several years of combined hormone therapy modestly raise breast cancer incidence, as long-term Women's Health Initiative follow-up showed 5. For average-risk women in their 40s, the benefit is real but smaller, so reasonable people weigh the harms differently 2, which is part of why guidelines disagree. Screening is not recommended in adolescence or the 20s, when cancer is rare, and the case strengthens across the perimenopausal and postmenopausal years 1.

When weighing mammogram benefits and harms needs a clinician

Deciding whether the benefits of screening outweigh the harms for you is a personal judgment that a clinician can help clarify. A primary care clinician or gynecologist can estimate your individual risk, walk through the numbers, and translate them into a plan that reflects your values 2. The well-woman visit is a good place to have that conversation and revisit it over time 4. Reasons to seek review include a new breast lump or skin change, which calls for evaluation regardless of your screening choices. Seeing how often to screen and what age to begin can help you frame questions, and Gale can help you prepare for the visit.

Common questions

For most average-risk women, yes. Regular screening lowers the chance of dying from breast cancer, which is the main benefit. The trade-off is false positives and a smaller risk of overdiagnosis. Experts generally judge the benefit worth the harms for average-risk women, but how you weigh anxiety, extra imaging, and possible overtreatment is a personal call worth discussing with a clinician.

About half of women screened every year for 10 years will have at least one false positive, meaning a callback for something that turns out not to be cancer. A smaller number will have a biopsy that comes back benign. Screening every two years rather than every year roughly halves the cumulative false-positive rate while keeping most of the benefit.

Overdiagnosis is when screening finds a cancer that never would have caused symptoms or shortened your life, yet it still gets treated. Because doctors cannot tell in advance which tumors are harmless, some women are treated unnecessarily. Estimates of how often this happens vary widely, which is one reason guidelines disagree about screening intensity.

Not for most women. The harms are real but generally outweighed by the benefit for average-risk women, especially from their 50s onward. The harms matter most for women in their 40s, where the benefit is smaller, and for older women with limited life expectancy. Your personal risk and values should guide the decision with a clinician.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Breast changes that need evaluation regardless of screening

  • —A new breast lump, thickening, or armpit swelling is a reason to seek clinician review, separate from any routine screening.
  • —Skin dimpling, puckering, or a newly inverted nipple is a reason to arrange a clinician visit.
  • —Spontaneous bloody or clear discharge from one nipple is a reason to be evaluated by a clinician.
  • —Persistent breast redness, swelling, or warmth is a reason to seek prompt clinician review.

This article is general health education, not medical advice. Whether the benefits of mammography outweigh the harms for you depends on your age, risk, and values, and is best decided with a primary care clinician or gynecologist.

References

  1. 1.National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025). Breast Cancer Screening. National Cancer Institute (NCI), NIH. link ✓National Cancer Institute patient screening summary; supports that mammography reduces breast cancer mortality, that about half of women screened annually for 10 years have a false positive, and that overdiagnosis occurs with widely varying estimates.
  2. 2.American College of Obstetricians and Gynecologists (2017). Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002158 ✓ACOG average-risk breast screening guidance; supports that the absolute benefit is smaller for women in their 40s and that screening decisions are individualized to risk and values.
  3. 3.National Cancer Institute (2024). BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. National Cancer Institute (NCI), NIH. link ✓National Cancer Institute BRCA fact sheet; supports that higher-risk women, including BRCA carriers, gain more benefit and are advised to start earlier, more intensive screening.
  4. 4.American College of Obstetricians and Gynecologists (2018). ACOG Committee Opinion No. 755: Well-Woman Visit. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002897 ✓ACOG well-woman visit guidance; supports the periodic visit as the place for shared decisions about screening over time.
  5. 5.Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. doi:10.1001/jama.2020.9482 ✓Long-term Women's Health Initiative follow-up (Chlebowski 2020); supports that combined estrogen-progestin therapy modestly increases breast cancer incidence, a personal risk factor in the screening decision.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library